中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

124 records (took 0.041 seconds)

    Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity
    12.
    发明授权
    Bacterial host strain comprising a mutant spr gene and having reduced Tsp activity 有权
    细菌宿主菌株包含突变体spr基因并具有降低的Tsp活性

    公开(公告)号：US09587227B2

    公开(公告)日：2017-03-07

    申请号：US14600089

    申请日：2015-01-20

    Applicant: UCB PHARMA, S.A.

    Inventor： Mark Ellis ,  David Paul Humphreys

    IPC: C12N9/04 ,  C07K14/245 ,  C12N9/52 ,  C12N15/70

    CPC classification number: C12N9/0006 ,  C07K14/245 ,  C12N9/52 ,  C12N15/70 ,  C12Y101/01

    Abstract: The present invention provides a recombinant gram-negative bacterial cell comprising a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, 170, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and wherein the cell has reduced Tsp protein activity compared to a wild-type cell.

    Abstract translation: 本发明提供了一种重组革兰氏阴性细菌细胞，其包含编码在选自D133，H145，H157，N31，R62,170，Q73，C94，S95，V98中的一个或多个氨基酸具有突变的spr蛋白的突变型spr基因 ，Q99，R100，L108，Y115，V135，L136，G140，R144和G147，并且其中与野生型细胞相比，细胞具有降低的Tsp蛋白活性。

    Recombinant Bacterial Host Cell for Protein Expression
    17.
    发明申请
    Recombinant Bacterial Host Cell for Protein Expression 有权
    用于蛋白表达的重组细菌宿主细胞

    公开(公告)号：US20150111249A1

    公开(公告)日：2015-04-23

    申请号：US14400068

    申请日：2013-05-13

    Applicant: UCB PHARMA S.A.

    Inventor： Philip Jonathan Bassett ,  David Paul Humphreys ,  Pareshkumar Manjibhai Patel

    IPC: C12P21/00

    CPC classification number: C12P21/00 ,  C07K16/283 ,  C07K2317/10 ,  C12N9/52 ,  C12N15/70 ,  C12P21/02

    Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a.) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b.) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti Fc Rn antibodies and proteins made by the methods described herein.

    Abstract translation: 本公开涉及重组革兰氏阴性细菌细胞，其包含：a）编码具有在一个或多个选自D133，H145，H157，N31，R62，I70，Q73， C94，S95，V98，Q99，R100，L108，Y115，V135，L136，G140，R144和G147，以及b）能够表达或过表达能够促进蛋白质折叠的一种或多种蛋白质的基因，例如FkpA，Skp， SurA，PPiA和PPiD，其中所述细胞与野生型细胞相比具有降低的Tsp蛋白活性，使用所述细胞的方法，所述细胞在蛋白质表达特别抗体中的用途，例如抗Fc Rn抗体和由 本文描述的方法。

    Antibodies specific for sclerostin and methods for increasing bone mineralization
    18.
    发明授权
    Antibodies specific for sclerostin and methods for increasing bone mineralization 有权
    针对硬皮蛋白的特异性抗体和增加骨矿化的方法

    公开(公告)号：US09011856B2

    公开(公告)日：2015-04-21

    申请号：US13670259

    申请日：2012-11-06

    Applicant: UCB Pharma S.A.

    Inventor： David G. Winkler ,  Jiye Shi ,  John Latham

    IPC: A61K39/395 ,  C07K16/18 ,  G01N33/53 ,  C07K16/22 ,  C07K14/51

    CPC classification number: C07K16/22 ,  A61K47/643 ,  A61K47/646 ,  C07K14/475 ,  C07K14/51 ,  C07K16/18 ,  C07K2317/76 ,  G01N33/6854 ,  G01N2333/4704

    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

    Abstract translation: 提供了与特异性结合TGF-β结合蛋白的抗体相关的组合物和方法。 这些方法和组合物涉及通过干扰TGF-β结合蛋白质硬化蛋白和TGF-β超家族成员，特别是骨形态发生蛋白之间的相互作用来改变骨矿物质密度。 增加骨矿物质密度在低骨矿物质密度代表骨质减少症，骨质疏松症和骨折等疾病和病症中具有应用价值。

Patent Agency Ranking